Company intelligence / Profile preview

Endolipid Therapeutics

Barcelona, Catalonia, Spainendolipid.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has conducted in vitro and in vivo experiments with positive results and plans to continue studies in animal models before advancing to human trials. They expect their technology to reach the market for treating non-alcoholic fatty liver disease within five years from 2021.

Therapeutic areas: GastroenterologyDermatology
Modalities: Peptides (SHBG-mimic peptides)
Industry: Biotech

Drug pipeline

2 assets

EDL6D

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

VHIR (Vall d'Hebron Institut de Recerca)Genesis Ventures

Beyond the preview

Go deeper on Endolipid Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endolipid Therapeutics.

Explore the full profile